Skip to main content

Coloplast A/S – Announcement no. 07/2020 – Coloplast strengthens Executive Management

Written by Customer Service on . Posted in Public Companies.

Coloplast strengthens Executive Management to deliver on upcoming 2025 strategy centred around innovation and growthToday, the Board of Directors have decided to expand the Executive Leadership Team from four members to six members as of 1 October 2020.The expansion aims to support the upcoming strategy which will focus on innovation and growth. A new Innovation Executive Vice President position position with responsibility for the company’s commercial offering and combining marketing, R&D and select global functions will be led by Nicolai Buhl Andersen. A new Growth Executive Vice President position position which combines the chronic care sales organization and the Wound & Skin care SBU will be led by Paul Marcun. Finally, HR is renamed People & Culture and elevated to the Executive leadership team to be led by Camilla G. Møhl.Nicolai Buhl Andersen is appointed Executive Vice President, Innovation and member of the Executive Leadership Team. Since joining Coloplast in 2005, Nicolai has held various senior management roles in the company including Head of Ostomy Care, Head of Sales, Nordic Region and Commercial Excellence. For the last 10 years, Nicolai has been SVP, Global Wound Care. Nicolai holds a Master’s degree in Economics and Marketing from Copenhagen Business School and Sophia University, Japan.Camilla G. Møhl is appointed Senior Vice President, People & Culture and member of the Executive Leadership Team. Since joining Coloplast in 2016, Camilla has been VP, Global HR Commercial Organization and was promoted to VP Global HR in 2019. Prior to joining Coloplast, Camilla gained more than 15 years’ experience within HR at large international companies including Carlsberg and Mars. Camilla holds a Master’s degree in Human Resources Management from Copenhagen Business School.“We are currently in the process of finalising our 2025 strategy, which will be launched at our Capital Markets Day at the end of September. As we look towards 2025, and strive to continue to deliver value for our shareholders, users, employees, healthcare professionals and partners, Innovation and Growth will be key strategic themes. To set ourselves up to deliver on our 2025 strategy, we’ve decided to expand our Executive Leadership Team and create new roles to match these strategic themes. I am happy to welcome Nicolai and Camilla to the team. Strong, passionate leaders, with strong followership, who live and breathe the Coloplast values,” says President & CEO Kristian Villumsen.“By expanding the Coloplast Executive Leadership Team, we are taking the first steps to secure a successful execution of the company’s 2025 strategy. Innovation and growth have characterised Coloplast for more than 60 years, and I am confident that this leadership team is well-equipped to deliver solid growth and life-changing innovations in the years to come,” says Chairman Lars Rasmussen.As of 1 October 2020, the Executive Leadership Team will consist of:President & CEO, Kristian Villumsen
Executive Vice President, Innovation, Nicolai Buhl Andersen
Executive Vice President & CFO, Anders Lonning-Skovgaard
Executive Vice President, Growth, Paul Marcun
Senior Vice President, People & Culture, Camilla G. Møhl
Executive Vice President, Global Operations, Allan RasmussenLars Rasmussen
Chairman of the Board 
For more information, please contact:Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 / 4911 3376
E-mail dkebj@coloplast.comRasmus Sørensen
Senior Manager, Investor Relations
Tel. +45 4911 1800 / 4911 1786
E-mail dkraso@coloplast.comPress and the media
Lina Danstrup
Senior Media Relations Manager, Corporate Communications
Tel. +45 4911 2607
E-mail dklina@coloplast.comWebsite
www.coloplast.comAddress
Coloplast A/S
Holtedam 1
DK-3050 Humlebæk
DenmarkBusiness reg. (CVR) no. 69749917 This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.The Coloplast logo is a registered trademark of Coloplast A/S. © 2020-08.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.Attachment07_2020_Coloplast strengthens Executive Management

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.